Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis ($NVS) multiple sclerosis drug in line for ...

Editor's Note: Published in JAMA Neurology this past October, the GATE Trial [1] was the first phase 3 study of a generic version of a multiple sclerosis (MS) disease therapy. Medscape recently ...

Specialty drugs, especially biologics, will constitute a significant portion of global drug spending by 2029, driven by cancer care costs. Autoimmune diseases and multiple sclerosis are key short-term ...

Replacing high-cost generics with cheaper medications that have the same clinical benefit could have cut down spending and saved patients about 88%, according to Johns Hopkins research published in ...

The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this ...

The timing of a generic drug's market entry may be determined by "pay for delay" patent settlements between drug companies. The generic drug sector in the US helps hold down pharmaceutical costs, with ...